FY2025 Earnings Forecast for BioSyent Issued By Bloom Burton

Key Points

• Bloom Burton has revised its FY2025 earnings per share estimate for BioSyent to $0.74, down from $0.75, while the current consensus estimate stands at $0.69.
• BioSyent announced a quarterly dividend of $0.05 per share, with a yield of 1.7%, scheduled for payment on September 15th.
• As of Wednesday, BioSyent's shares are trading at C$12.05, with a market capitalization of C$137.82 million and a P/E ratio of 19.56.

BioSyent Inc. (CVE:RX - Free Report) - Research analysts at Bloom Burton cut their FY2025 EPS estimates for BioSyent in a note issued to investors on Monday, August 25th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of $0.74 per share for the year, down from their prior forecast of $0.75. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share.

BioSyent Trading Down 0.3%

Shares of CVE:RX traded down C$0.04 during trading on Wednesday, reaching C$12.07. The stock had a trading volume of 9,415 shares, compared to its average volume of 4,185. The business has a fifty day moving average price of C$11.62 and a 200-day moving average price of C$11.27. The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90. The stock has a market cap of C$135.86 million, a P/E ratio of 16.99 and a beta of 0.45. BioSyent has a fifty-two week low of C$9.20 and a fifty-two week high of C$12.40.

BioSyent Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 29th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 1.7%. BioSyent's dividend payout ratio (DPR) is 26.76%.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.